SCHEMBL9608310

SCHEMBL9608310

CC(C)Cn1c(=O)n(C)c(=O)c2c(Nc3ccc(O)cc3)n(Cc3ccc(C(C)(F)F)cc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 10/20 0.41
PDE1A P54750 9/20 0.41
PDE1C Q14123 9/20 0.41
PDE2A O00408 8/20 0.41
SLC16A1 P53985 2/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
PDE4D Q08499 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 1/20 0.33
KMT2A Q03164 1/20 0.32
ADRA2A P08913 1/20 0.32
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13334342 0.94 PDE1A (0.41) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL9608307 0.91 PDE1B (0.48) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL9608344 0.90 MAPT (0.34) PDE1BPDE2AALDH1A1MAPTPOLB
SCHEMBL2455942 0.85 PDE1B (0.48) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL13334360 0.84 LMNA (0.38) PDE1BPDE2AALDH1A1MAPTPOLB
SCHEMBL9608345 0.84 PDE1B (0.35) PDE1BPDE1APDE1CPDE2AMAPT
SCHEMBL16369451 0.83 PDE1B (0.41) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL9608334 0.79 PDE1B (0.52) PDE1BPDE1APDE1CPDE2ASLC16A1
SCHEMBL16378553 0.78 PDE4A (0.38) PDE1BPDE1APDE1CPDE2AMAPT
SCHEMBL9608338 0.77 PDE1B (0.44) PDE1BPDE1APDE1CPDE2ASLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353556-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-12-10 US disclosed
US-8927556-B2 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds INTRA-CELLULAR THERAPIES, INC. (US) 2015-01-06 US disclosed
US-20120136013-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES. INC. 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353556-A1 ORGANIC COMPOUNDS CYP2C9, TPMT, CYP2C19 PDE1B 4863/4885PDE1A 4874/4885PDE1C 4862/4885
US-20120136013-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.